M. J. Van-den-bent, M. Smits, J. M. Kros, and S. M. Chang, Diffuse Infiltrating Oligodendroglioma and Astrocytoma, J. Clin. Oncol, vol.35, pp.2394-2401, 2017.

P. Wesseling and D. Capper, Classification of gliomas, Neuropathol. Appl. Neurobiol, vol.44, pp.139-150, 2016.

I. Tirosh, Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma, Nature, vol.539, pp.309-313, 2016.

A. S. Venteicher, Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq, Science, p.355, 2017.

M. S. Waitkus, B. H. Diplas, and H. Yan, Isocitrate dehydrogenase mutations in gliomas, Neuro-oncology, vol.18, pp.16-26, 2016.

H. Duffau, Diffuse low-grade glioma, oncological outcome and quality of life: a surgical perspective, Curr. Opin. Oncol, vol.30, pp.383-389, 2018.

Z. Bao, RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas, Genome Res, vol.24, pp.1765-1773, 2014.

H. Bai, Integrated genomic characterization of IDH1-mutant glioma malignant progression, Nat. Genet, vol.48, pp.59-66, 2016.

Z. Pedeutour-braccini, Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification? Virchows Arch, vol.466, pp.433-444, 2015.

C. Gozé, 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth, J. Neurooncol, vol.108, pp.69-75, 2012.

P. Guichet, Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors, Glia, vol.61, pp.225-239, 2013.

S. Azar, Cellular and molecular characterization of IDH1-mutated diffuse low-grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFR? activation, Glia, vol.66, pp.239-255, 2018.

K. Yoshihara, Inferring tumour purity and stromal and immune cell admixture from expression data, Nat. Commun, vol.4, p.2612, 2013.

M. Deng, J. Brägelmann, J. L. Schultze, and S. Perner, Web-TCGA: an online platform for integrated analysis of molecular cancer data sets, BMC Bioinformatics, vol.17, p.72, 2016.

Q. Liu, Q. Luo, A. Halim, and G. Song, Targeting lipid metabolism of cancer cells: A promising therapeutic strategy for cancer, Cancer Lett, vol.401, pp.39-45, 2017.

D. Schiroli, S. Cirrincione, S. Donini, and A. Peracchi, Strict reaction and substrate specificity of AGXT2L1, the human O-phosphoethanolamine phospho-lyase, IUBMB Life, vol.65, pp.645-650, 2013.

G. R. Brown, Gene: a gene-centered information resource at NCBI, Nucleic Acids Res, vol.43, pp.36-42, 2015.

Y. Zhang, Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse, Neuron, vol.89, pp.37-53, 2016.

L. Sun, Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain, Cancer Cell, vol.9, pp.287-300, 2006.

S. Madhavan, Rembrandt: helping personalized medicine become a reality through integrative translational research, Mol. Cancer Res, vol.7, pp.157-167, 2009.

H. Yu, H. Lee, A. Herrmann, R. Buettner, and R. Jove, Revisiting STAT3 signalling in cancer: new and unexpected biological functions, Nat. Rev. Cancer, vol.14, pp.736-746, 2014.

H. Lo, X. Cao, H. Zhu, and F. Ali-osman, Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators, Clin. Cancer Res, vol.14, pp.6042-6054, 2008.

H. Su, Cell confluence-induced activation of signal transducer and activator of transcription-3 (Stat3) triggers epithelial dome formation via augmentation of sodium hydrogen exchanger-3 (NHE3) expression, J. Biol. Chem, vol.282, pp.9883-9894, 2007.

T. A. Doucette, Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma, Neuro-oncology, vol.14, pp.1136-1145, 2012.

J. V. Alvarez, A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis, Transl. Oncogenomics, vol.2, pp.99-105, 2007.

M. M. Sherry, A. Reeves, J. K. Wu, and B. H. Cochran, STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells, Stem Cells, vol.27, pp.2383-2392, 2009.

C. Villalva, STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?, Int. J. Cancer, vol.128, pp.826-838, 2011.

M. S. Carro, The transcriptional network for mesenchymal transformation of brain tumours, Nature, vol.463, pp.318-325, 2010.

N. M. Warrington, Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1, Cancer Res, vol.70, pp.5717-5727, 2010.

Y. Lee, J. Lee, S. H. Ahn, J. Lee, and D. Nam, WNT signaling in glioblastoma and therapeutic opportunities, Lab. Invest, vol.96, pp.137-150, 2016.

H. K. Lee and B. Deneen, Daam2 is required for dorsal patterning via modulation of canonical Wnt signaling in the developing spinal cord, Dev. Cell, vol.22, pp.183-196, 2012.

Y. Liu, Secreted frizzled-related protein 2-mediated cancer events: Friend or foe?, Pharmacol. Rep, vol.69, pp.403-408, 2017.

P. Esteve and P. Bovolenta, The advantages and disadvantages of sfrp1 and sfrp2 expression in pathological events, Tohoku J. Exp. Med, vol.221, pp.11-17, 2010.

A. Lanciotti, Megalencephalic leukoencephalopathy with subcortical cysts protein-1 regulates epidermal growth factor receptor signaling in astrocytes, Hum. Mol. Genet, vol.25, pp.1543-1558, 2016.

C. Giaume and L. Venance, Gap junctions in brain glial cells and development, Perspect. Dev. Neurobiol, vol.2, pp.335-345, 1995.

S. D. Konduri, Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells, Oncogene, vol.21, pp.8705-8712, 2002.

S. Yu, Connexin 43 reverses malignant phenotypes of glioma stem cells by modulating E-cadherin, Stem Cells, vol.30, pp.108-120, 2012.

Q. Ding, AGXT2L1 is down-regulated in heptocellular carcinoma and associated with abnormal lipogenesis, J. Clin. Pathol, vol.69, pp.215-220, 2016.

M. Uhlén, Tissue-based map of the human proteome, Science, vol.347, 2015.

A. E. Boukouris, S. D. Zervopoulos, and E. D. Michelakis, Metabolic Enzymes Moonlighting in the Nucleus: Metabolic Regulation of Gene Transcription, Trends Biochem. Sci, vol.41, pp.712-730, 2016.

R. G. Verhaak, Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, vol.17, pp.98-110, 2010.

T. Kano-sueoka and J. E. Errick, Effects of phosphoethanolamine and ethanolamine on growth of mammary carcinoma cells in culture, Exp. Cell Res, vol.136, pp.137-145, 1981.

I. Ajioka, T. Akaike, and Y. Watanabe, Ethanolamine is a co-mitogenic factor for proliferation of primary hepatocytes, J. Cell Biochem, vol.84, pp.249-263, 2002.

M. Esmaeili, IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma, Cancer Res, vol.74, pp.4898-4907, 2014.